Reference SummaryBortner DM, Mol Cell Biol 1997 Jan;17(1):453-9
Title |
Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. |
Authors |
Bortner DM; Rosenberg MP |
Journal |
Mol Cell Biol |
Volume |
17 |
Issue |
1 |
Year |
1997 |
Pages |
453-9 |
Abstract |
Deregulated expression of several cell cycle regulatory genes has been demonstrated to be associated with cancer. In particular, a strong correlation has been established between inappropriate cyclin E expression and human breast cancer. To determine the ability of cyclin E to play a causative role in mammary tumorigenesis, regulatory sequences from the ovine beta-lactoglobulin gene were utilized to specifically target expression of human cyclin E to the mammary glands of pregnant and lactating mice. Lactating mammary glands of transgenic mice expressing cyclin E contained areas of hyperplasia, primarily papillary projections of hyperplastic cells, which were rarely observed in lactating glands of control mice. Over 10% of female cyclin E transgenic mice have developed mammary carcinomas, with latencies ranging from 8 to 13 months. Tumor analysis revealed the presence of transgene-specific cyclin E RNA and protein, as well as cyclin E- and cdk2-associated kinase activity, suggesting that cyclin E is likely a contributing component of tumorigenic progression in this model system. |
Links |
J:56329 – MGI References 8972226 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| B6;C3-Tg(BLG-CCNE1)2083Mpr | Eye - Harderian gland adenocarcinoma | Eye - Harderian gland |
14 |
||
| B6;C3-Tg(BLG-CCNE1)2083Mpr | Eye - Harderian gland adenoma | Eye - Harderian gland |
14 |
||
| B6;C3-Tg(BLG-CCNE1)2426Mpr | Eye - Harderian gland adenoma | Eye - Harderian gland |
33 |
||
| B6;C3-Tg(BLG-CCNE1)2463Mpr | Leukocyte lymphoma | Leukocyte |
9.1 |
||
| [not specified]-Trp53tm1Tyj/? | Leukocyte lymphoma | Leukocyte |
observed |
||
| B6C3F2-Tg(BLG-CCNE1)2359Mpr | Mammary gland adenocarcinoma - acinar | Mammary gland |
100 |
||
| B6;C3-Tg(BLG-CCNE1)2458Mpr | Mammary gland adenocarcinoma - acinar | Mammary gland |
10 |
||
| B6;C3-Tg(BLG-CCNE1)2463Mpr | Mammary gland adenocarcinoma - acinar | Mammary gland |
27 |
||
| B6;C3-Tg(BLG-CCNE1)2066Mpr | Mammary gland hyperplasia - papillary | Mammary gland |
observed |
||
| B6;C3-Tg(BLG-CCNE1)2083Mpr | Mammary gland hyperplasia - papillary | Mammary gland |
observed |
||
| B6;C3-Tg(BLG-CCNE1)2426Mpr | Mammary gland hyperplasia - papillary | Mammary gland |
observed |
||
| B6;C3-Tg(BLG-CCNE1)2458Mpr | Mammary gland hyperplasia - papillary | Mammary gland |
observed |
||
| B6;C3-Tg(BLG-CCNE1)2463Mpr | Mammary gland hyperplasia - papillary | Mammary gland |
observed |
||
| B6;C3-Tg(BLG-CCNE1)2066Mpr | Mammary gland tumor | Mammary gland |
0 |
||
| B6;C3-Tg(BLG-CCNE1)2083Mpr | Mammary gland tumor | Mammary gland |
0 |
||
| B6;C3-Tg(BLG-CCNE1)2426Mpr | Mammary gland tumor | Mammary gland |
0 |
||
| B6;C3-Tg(BLG-CCNE1)2458Mpr | Mammary gland tumor | Mammary gland |
0 |
||
| B6;C3-Tg(BLG-CCNE1)2463Mpr | Mammary gland tumor | Mammary gland |
0 |
||
| [not specified] | Mammary gland tumor | Mammary gland |
0 |
||
| B6;C3-Tg(BLG-CDK2)1258Mpr | Mammary gland tumor | Mammary gland |
observed |
||
| C3H/HeOuJ | Mammary gland tumor |
|
Mammary gland |
observed |
|
| B6;C3-Tg(BLG-CCNE1)2066Mpr | (Unspecified organ) tumor | (Unspecified organ) |
0 |
||
| B6;C3-Tg(BLG-CCNE1)2083Mpr | (Unspecified organ) tumor | (Unspecified organ) |
29 |
||
| B6C3F2-Tg(BLG-CCNE1)2359Mpr | (Unspecified organ) tumor | (Unspecified organ) |
100 |
||
| B6;C3-Tg(BLG-CCNE1)2426Mpr | (Unspecified organ) tumor | (Unspecified organ) |
33 |
||
| B6;C3-Tg(BLG-CCNE1)2458Mpr | (Unspecified organ) tumor | (Unspecified organ) |
10 |
||
| B6;C3-Tg(BLG-CCNE1)2463Mpr | (Unspecified organ) tumor | (Unspecified organ) |
36 |
||
| [not specified] | (Unspecified organ) tumor | (Unspecified organ) |
0 |